Phase I therapy trials in children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 5, 1998, Pages 431-438

  Shah, Shafqat ^a   Weitman, Steven ^a   Langevin, Anne Marie ^a   Bernstein, Mark ^b   Furman, Wayne ^c   Pratt, Charles ^c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Pediatric oncology; Phase I trials

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 6 DIAZO 5 OXONORLEUCINE; ACIVICIN; AMSACRINE; ANCITABINE; ANTINEOPLASTIC AGENT; BETA INTERFERON; BISANTRENE; CARBOPLATIN; DEOXYTHIOGUANOSINE; DIAZIQUONE; ESORUBICIN; ETOPOSIDE; FAZARABINE; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; INDICINE N OXIDE; INTERLEUKIN 2; IPROPLATIN; MITOFLAXONE; MITOXANTRONE; PACLITAXEL; PENTOSTATIN; RAZOXANE; RETINOIC ACID; TAU INTERFERON; UNINDEXED DRUG; ZINOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; HUMAN; NEUROBLASTOMA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 0032465981     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199809000-00005     Document Type: Article

References (65)

1. Ratain MJ, Collyar D, Kamen B, et al. Critical role of phase I clinical trials in cancer treatment. J Clin Oncol 1997;15:853-9.
2. Furman WE, Pratt CB, Rivera GK, et al. Mortality in pediatric phase I clinical trials. J Natl Cancer Inst 1989;81:1193-4.
3. Rivera G, Evans WE, Dahl GV, et al. Phase I clinical and pharmacokinetic study of 4′(9-Acridinylamino)-methanesulfon-m-anisidide in children with cancer. Cancer Res 1980;40:4250-3.
4. Smith MA, Adamson PC, Balis FM, et al. Phase I and pharmacokinetic evaluation of All-Trans-Retinoic Acid in pediatric patients with cancer. J of Clin Oncol 1992;10:1666-73.
5. Baruchel S, Bernstein M, Whitehead M, et al. A phase I study of acivicin in refractory pediatric solid tumors. Invest New Drugs 1995;13:211-6.
6. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-AZA-deoxycytidine in children with acute leukemia. Leuk Res 1981;5:453-62.
7. Tan CTC, Hancock CH, Mondora A, et al. Phase I study of aziridinyl-benzoquinone (AZQ, NSC 182986) in children with cancer. Cancer Res 1984;44:831-5.
8. Pratt CB, Sinkule JA, Etcubanas E, et al. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors. Invest New Drugs 1986;4:149-53.
9. Bacha DM, Caparros-Sison B, Allen JA, et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986;70:865-9.
10. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep 1987;71:1039-42.
11. Ettinger LJ, Krailo MD, Gaynon PS, et al. A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. Cancer 1993;72: 917-22.
12. Santana VM, Mirro, Jr. J, Harwood FC, et al. A phase 1 clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991;9:416-22.
13. Finklestein JZ, Higgins G, Krivit W, et al. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep 1979;63:1331-3.
14. Poplack DG, Sallan SE, Rivera G, et al. Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 1981;41:3343-6.
15. Pratt CB, Douglass EC, Meyer WH, et al. Phase I study of 4′-deoxydoxorubicin (esorubicin) in children with malignant solid tumors. Invest New Drugs 1989;7:209-11.
16. Higgins GR, Jamin DC, Shore NA, et al. Phase I evaluation of β-2′-deoxythioguanosine in pediatric patients with leukemia. Cancer Treat Rep 1985;69:699-701.
17. Ettinger LJ, Siegel SE, Belasco JB, et al. Phase 1 clinical evaluation of diaziquone in childhood cancer. Cancer Treat Rep 1985;69:323-7.
18. Falletta JM, Gushing B, Lauer S, et al. Phase I evaluation of diaziquone in childhood cancer. Invest New Drugs 1990;8:167-70.
19. Sullivan MP, Nelson JA, Feldman S, et al. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharmacol 1988;21:78-84.
20. Mathew P, Ribeiro RC, Sonnichsen D, et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 1994;12:1452-7.
21. Bernstein ML, Whitehead VM, Grier H, et al. A phase I trial of fazarabine in refractory pediatric solid tumors: a Pediatric Oncology Group study. Invest New Drugs 1993;11:309-12.
22. Heideman RL, Gillespie A, Ford H, et al. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res 1989;49:5213-6.
23. Pratt CB, Relling MV, Meyer WH, et al. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am J Clin Oncol 1991;14:483-6.
24. Avramis VI, Champagne J, Sato J, et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990;50:7226-31.
25. Green DM, Krischer JP, Bell B, et al. Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 1990;18:321-4.
26. Tan CTC, Luks E, Bacha DM et al. Phase I trial of homoharringtonine in children with refractory leukemia. Cancer Treat Rep 1987;71:1245-8.
27. Holcenberg JS, Tutsch KD, Earhart RH, et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986;70:703-9.
28. Tan CTC, Hancock, Steinherz P, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 1987;47:2990-5.
29. Pui C-H, de Graaf SSN, Dow LW, et al. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1988;48:5348-52.
30. Pratt CB, Meyer WH, Douglass EC, et al. A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer 1993;71:3661-5.
31. Pratt CB, Douglass EC, Kovnar EH, et al. A phase I study of ifosfamidc given on alternate days to treat children with brain tumors. Cancer 1993;71:3666-9.
32. Whitehead VM, Bernstein ML, Vega R, et al. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Cancer Chemother Pharmacol 1990;26:377-9.
33. Allen J, Packer R, Bleyer A, et al. Recombinant interferon beta: A phase I/II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:783-8.
34. Mahmoud HH, Pui C-H, Kennedy W, et al. Phase I study of recombinant human interferon gamma in children with relapsed acute leukemia. Leukemia 1992;6:1181-4.
35. Roper M, Smith MA, Sondel PM, et al. A phase I study of interleukin-2 in children with cancer. Am J Pediatr Hematol Oncol 1992;14:305-11.
36. Nasr S, McKolanis J, Pais R, et al. A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy: A Pediatric Oncology Group study. Cancer 1989;64:783-8.
37. Pais RC, Abdel-Mageed A, Ghim TT, et al. Phase I study of recombinant human interleukein-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study. J Immunother 1992;12:138-46.
38. Lashford LS, Lewis IJ, Fielding SK, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.
39. Pratt CB, Kamen BA, Winick N, et al. Phase I study of iproplatin in pediatric patients: a Pediatric Group Study. Cancer Treat Rep 1987;71:87-8.
40. Ungerleider RS, Pratt CB, Vietti TJ, et al. Phase I trial of mitoxantrone in children. Cancer Treat Rep 1985;49:403-7.
41. Starling KA, Mulne AF, Vats TS, et al. Mitoxantrone in refractory acute leukemia in children: a phase I study. Invest New Drugs 1985;3:191-5.
42. Rivera G, Howarth C, Aur RJA, et al. Phase I study of neocarzinostatin in children with cancer. Cancer Treat Rep 1978;62:2105-7.
43. Murphy SB, Mirro J, Pui C-H, et al. Phase I trial of N-methylformamide in pediatric patients with refractory leukemia. Cancer Treat Rep 1987;12:1229-30.
44. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 1993;11:2324-9.
45. Adamson PC, Balis FM, Miser J, et al. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 1992;52:521-4.
46. Adamson PC, Balis FM, Miser J, et al. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res 1990;50:4464-7.
47. Van Eys J, Cangir A, Pack R, et al. Phase I trial of procarbazine as a 5-day continuous infusion in children with central nervous system tumors. Cancer Treat Rep 1987;71:973-4.
48. Tan CTC, Mitta SK, Steinherz L, et al. Phase I trial of rubidazone (NSC 164011) in children with cancer. Med Ped Oncol 1981;9:347-53.
49. Heideman RL, Kelley JA, Packer RJ, et al. A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res 1988;48:2292-5.
50. Pratt CB, Bowman LC, Marina N, et al. A phase I study of sulofenur in refractory pediatric malignant solid tumors. Invest New Drugs 1995;13:63-6.
51. Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989;49:736-41.
52. Balis FM, Lange BJ, Packer RJ, et al. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res 1985;45:5169-72.
53. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993;53:1032-6.
54. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
55. Balis FM, Patel R, Luks E, et al. Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987;47:4973-6.
56. Pappo AS, Vats T, Williams TE, et al. Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Ped Oncol 1993;21:280-2.
57. Furman WL, Strother D, McClain K, et al. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 1993;11:2205-10.
58. Komp D, Vats T, Shepherd DA, et al. Phase I evaluation of vindesine in children: a Southwest Oncology Group Pilot Study. Med Fed Oncol 1980;8:243-50.
59. Von Hoff DD, Turner J, Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9:115-22.
60. Decoster G, Stein G, Holdener EE, Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990;1:175-81.
61. Estey E, Hoth D, Simon R, et al. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 1986;70:1105-15.
62. Weitman S, Ochoa S, Sullivan J, et al. Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1997;19:187-91.
63. Ratain MJ, Mick R, Schilsky R, et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993;85:1637-43.
64. Arbuck SG. Workshop on phase I study design. Ann Oncol 1996;7:567-73.
65. Leventhal BG and Graham ML. Clinical trials in pediatric oncology. Semin Oncol 1988;15:482-7.